Endometrium Adenokanserli Hastalarda Preoperatif Hematolojik Parametrelerin Değerlendirilmesi

Serkan Kumbasar; Dilruba Karaca; Fatma Ketenci Gencer; Özlem Khatip; Hatice Yaşat Nacar; Nazime Binnur Cömert; Esra Nazlı Döktür

doi:10.4274/BMB.galenos.2022.2022-10-088

Endometrium Adenokanserli Hastalarda Preoperatif Hematolojik Parametrelerin Değerlendirilmesi

PDF

Özgün Araştırma

Endometrium Adenokanserli Hastalarda Preoperatif Hematolojik Parametrelerin Değerlendirilmesi

Bagcilar Med Bull 2023;8(1):6-12 DOI: 10.4274/BMB.galenos.2022.2022-10-088

, , , , ,

PDF

İzin

Öz

Amaç:

Çalışmamızın amacı düşük riskli ve orta ileri riskli endometrium kanseri tanısı konan hastalar ile benign endometriyal patoloji tanısı konan hastaların ortalama trombosit hacmi (MPV), platelet dağılım genişliği (PDW), nötrofil/lenfosit oranı (NLO), monosit lenfosit oranı (MLO), eozinofil lenfosit oranı (ELO), trombosit/lenfosit oranı (PLO) değerlerini karşılaştırmaktır.

Yöntem:

Çalışmamıza Mart 2014-Nisan 2022 tarihlerinde hastanemizde anormal uterin kanama ön tanısıyla histeroskopi, dilatasyon küretaj ya da endometriyal biyopsi ile endometriyal örnekleme yapılan hastalar dahil edilmiştir. Endometriyal örnekleme sonuçlarına göre gruplar; benign grup, malign grup olarak isimlendirildi. Ek olarak; malign grup kendi arasında intraoperatif frozen değerlendirme ve postoperatif kesin patoloji sonucuna göre iki gruba ayrılarak alt grup analizi yapıldı. Endometriyal patolojisi olmayanla grup 1, düşük riskli endomeriyal adenokanserli olgular grup 2, düşük riskili endometrun Ca dışındaki endometrum adenokanserli (orta ve daha ileri riskli endometrum adenokanserli) olgular grup 3 olarak tanımlandı.

Bulgular:

Gruplar arasında nötrofil sayısı, lenfosit sayısı, trombosit sayısı, eozinofil sayısı, MPV, PDW, NLO, MLO, ELO, PLO (p>0,05) açısından istatistiksel olarak anlamlı fark bulunmadı. Endometriyal kalınlık değeri, vücut kitle indeksi, ileri yaş endometriyal kanser grubunda anlamlı bulundu.

Sonuç:

Gruplar arasında MPV, NLO, ELO, MLO ve PLO değerleri istatistiksel açısından farklılık izlenmedi. Bunun sebebi düşük riskli ve de orta-yüksek riskli endometrium adenokanserinin sistemik enflamasyonu tetiklemediğinden kaynaklanmış olabilir.

Anahtar Kelimeler: Endometrium adenokanser, ELO, MNO, MPV, NLO, PLO

Kaynakça

1

Mantovani A. Cancer: Inflaming metastasis. Nature 2009;457(7225):36-37.

2

Schreiber RD, Old LJ, Smyth MJ: Cancer Immunoediting: Integrating Immunity’sRoles in Cancer Suppression and Promotion. Science 2011;331(6024):1565-1570.

3

Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol 2014;23(1):31-39.

4

Lee Y, Kim SH, Han JY, Kim HT, Yun T, Lee JS. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol 2012;138(12):2009-2016.

5

De Larco JE, Wuertz BRK, Furcht LT. The Potential Role of Neutrophils in Promoting the Metastatic Phenotype of Tumors Releasing Interleukin-8. Clin Cancer Res 2004;10(15):4895-4900.

6

Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21(2):137-148.

7

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436-444.

8

Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006;32(1):22-28.

9

Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest 2012;122(1):327-336.

10

Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001;102(1):5-14.

11

Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?. Int J Clin Oncol 2015;20(1):70-81.

12

Cedrés S, Torrejon D, Martínez A, Martinez P, Navarro A, Zamora E, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 2012;14(11):864-869.

13

Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost 2011;9(2):237-249.

14

Yasui S, Takata T, Kamitani Y, Mae Y, Kurumi H, Ikebuchi Y, et al. Neutrophil-to-Lymphocyte Ratio Is a Useful Marker for Predicting Histological Types of Early Gastric Cancer. J Clin Med 2021;10(4):791.

15

Yin X, Wu L, Yang H, Yang H. Prognostic significance of neutrophil-lymphocyte ratio (NLR) in patients with ovarian cancer. Medicine (Baltimore) 2019;98(45):e17475.

16

Sun Y, Zhang L. The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis. Cancer Manag Res 2018;10:6167-6179.

17

Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyteratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 2017;19(1):2.

18

Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366(9484):491-505.

19

Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer 2016;26(1):2-30.

20

Aoki A. Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013. J Obstet Gynaecol Res 2014;40(2):338-348.

21

Acmaz G, Aksoy H, Unal D, Ozyurt S, Cingillioglu B, Aksoy U, et al. Are Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios Associated with Endometrial Precancerous and Cancerous Lesions in Patients with Abnormal Uterine Bleeding?. Asian Pacific J Cancer Prev 2014;15(4)1689-1692.

22

Cooke EW, Pappas L, Gaffney DK. Does therevised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes?. Cancer 2011;117(18):4231-4237.

23

Hemalatha AN, Pai MR, Raghuveer CV. Endometrial aspiration cytology by various techniques. J Indian Med Assoc 2011;109(6):426-427.

24

Kim BW, Jeon YE, Cho H, Nam EJ, Kim SW, Kim S, et al. Pre-treatment diagnosis of endometrial cancer through a combination of CA125 and multiplication of neutrophil and monocyte. J Obstet Gynaecol Res 2012;38(1):48-56.

25

Mete Ural Ü, Şehitoğlu İ, Bayoğlu Tekin Y, Kir Şahin F. “Neutrophil-to-lymphocyteandplatelet-to-lymphocyteratios in patients with endometrial hyperplasia and endometrial cancer. J Obstet Gynaecol Res 2015;41(3):445-448.

26

Haruma T, Nakamura K, Nishida T, Ogawa C, Kusumoto T, Seki N, et al. Pre-treatment neutrophil to lymphocyte ratio is a predictor of prognosis in endometrial cancer. Anticancer Res 2015;35(1):337-343.

27

Yayla Abide C, Bostanci Ergen E, Cogendez E, Kilicci C, Uzun F, Ozkaya E, et al. Evaluation of complete blood count parameters to predict endometrial cancer. J Clin Lab Anal 2018;32(6):e22438.

28

Metindir J, Bilir Dilek G. Preoperative hemoglobin and platelet count and poor prognostic factors in patients with endometrial carcinoma. J Cancer Res Clin Oncol 2009;135(1):125-129.

29

Gücer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, et al. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol 1998;70(2):210-214.

30

Oge T, Yalcin OT, Ozalp SS, Isikci T. Platelet volume as a parameter for platelet activation in patients with endometrial cancer. J Obstet Gynaecol 2013;33(3):301-304.

31

Kılınçalp S, Ekiz F, Başar O, Ayte MR, Coban S, Yılmaz B, et al. Mean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelets 2014;25(8):592-594.

32

Can C, Baseskioglu B, Yılmaz M, Colak E, Ozen A, Yenilmez A. Pretreatment parameters obtained from peripheral blood sample predicts invasiveness of bladder carcinoma. Urol Int 2012;89(4):468-472.

33

Karateke A, Kaplanoglu M, Baloglu A. Relations of Platelet Indices with Endometrial Hyperplasia and Endometrial Cancer. Asian Pac J Cancer Prev 2015;16(12):4905-4908.

34

Temur I, Kucukgoz Gulec U, Paydas S, Guzel AB, Sucu M, Vardar MA. Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2018;226:25-29.

35

Temur M, Taşgöz FN, Dinçgez Çakmak B, Çift T, Üstünel S, Korkmazer E, et al. Relationship between endometrial thickness and neutrophil/lymphocyte ratio with endometrial malignancy in 386 postmenopausal uterine bleeding cases. J Obstet Gynecol Investig 2018;1:e29-e34.

36

Evani SJ, Prabhu RG, Gnanaruban V, Finol EA, Ramasubramanian AK. Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow. FASEB J 2013;27(8):3017-3029.

37

Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124(2):263-266.

38

Cummings M, Merone L, Keeble C, Burland L, Grzelinski M, Sutton K, et al. Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival. Br J Cancer 2015;113(2):311-320.

39

Njoku K, Ramchander NC, Wan YL, Barr CE, Crosbie EJ. Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis. Gynecol Oncol 2022;164(1):146-153.

40

Holub K, Biete A. New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer. BMC Cancer 2018;18(1):1280.